Iridium complex-based double-metal-center radiodynamic drug and preparation method thereof
An iridium complex and kinetic technology, applied in the field of medicine, can solve the problems of limited enhancement effect and no large-scale clinical application, and achieve the effects of reducing the attenuation length, improving the energy transfer efficiency, and increasing the attenuation coefficient.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0032] In this embodiment, R1 is selected from phenyl, X is selected from nitrogen atom, R2 is selected from methyl group; M is selected from holmium(III) ion.
[0033] When R1 is selected from phenyl, X is selected from nitrogen atom, and R2 is selected from methyl group, the radiodynamic drug tetrakis[bis(2,3-diphenylquinoxaline)·2,2'- Bipyridine-4,4'-dicarboxylate iridium(III)]·bis(acetic acid)diholmium(III)(Ir-M-1).
[0034] Its synthetic chemical formula is as figure 1 Shown, concrete its preparation process is:
[0035] 1. Preparation of intermediate bridged chloroiridium complex (Ir-1):
[0036] 2,3-diphenylquinoxaline (310.6mg, 1.1mmol) and IrCl 3 Hydrate (60% Ir, 160mg, 0.5mmol) was added to 5mL of H 2 O and 15mL of 2-methoxyethanol in a mixed solvent, then reflux and stir for 24h under the protection of an inert gas (argon). After cooling down to room temperature, add 5 mL of H 2 O, the ice bath was further cooled until a large amount of brown precipitates were...
Embodiment 2
[0042] Verification of X-ray absorption effect of radiodynamic drug (Ir-M-1) in solid state:
[0043] The Ir-2 and Ir-M-1 solid powders described in Example 1 are respectively placed in a 1mL centrifuge tube, and the emission spectrum at 365nm is tested on Edinburgh FLS 980 under the irradiation of X-rays (0.05Gy / h) .
[0044] figure 2 Represents the X-ray emission spectrum of the radiodynamic drug (Ir-M-1) with a double metal center described in Example 1 of the present invention and the iridium complex (Ir-2) that does not form a double metal center complex under solid .
[0045] In the figure: Ir-M-1 can be directly excited by X-rays in the solid state and emit red fluorescence, while Ir-2 hardly observes fluorescence emission;
[0046] From the above results, it can be seen that the bimetallic center structure involved in the present invention has better absorption of X-rays and higher energy transfer efficiency.
Embodiment 3
[0048] Verification of the Relative Generation of Hydroxyl Free Radicals (·OH) in Radiokinetic Drug (Ir-M-1) Aqueous Solutions under X-ray Irradiation:
[0049] 1. Prepare the Ir-2 and Ir-M-1 described in Example 1 into 1 mg / mL aqueous solution respectively, then add methylene blue with a final concentration of 0.25 mg / mL in the solution as a hydroxyl radical indicator, and use ultraviolet A spectrometer measures the absorbance of these solutions at 664 nm.
[0050] 2. After exposing the above solution to X-rays (0.25Gy), test the absorbance of the solution at 664nm again, and calculate the degradation rate of methylene blue.
[0051] like image 3 It means that the double metal center radiodynamic drug (Ir-M-1) described in Example 1 of the present invention and the iridium complex (Ir-2) that does not form a double metal center complex are irradiated by X-rays in an aqueous solution of the same concentration The relative generation content of hydroxyl radicals (·OH) is sho...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com